Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of lentinan in preparation of drug for preventing diabetes type 1

A technology of type 1 diabetes and lentinan, applied in the field of medicine, can solve the problem of not knowing that lentinan is equally effective for type 1 diabetes, and achieve the effects of improving serum insulin level, improving survival rate and relieving insulitis.

Inactive Publication Date: 2016-08-10
NANJING MEDICAL UNIV
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, those skilled in the art cannot know whether lentinan is also effective for type 1 diabetes according to its records

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lentinan in preparation of drug for preventing diabetes type 1
  • Use of lentinan in preparation of drug for preventing diabetes type 1
  • Use of lentinan in preparation of drug for preventing diabetes type 1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Effect of lentinan on the onset of type 1 diabetes in NOD mice.

[0034] Experimental animals: 4-5-week-old female NOD mice and feed, provided by Changzhou Cavens Experimental Animal Co., Ltd., license number: SCXK (Su) 2011-0003. Animals were housed in random cages, with free access to food and water.

[0035] Experimental drugs: Lentinan was purchased from Jiangsu Yongjian Pharmaceutical Technology Co., Ltd., and the negative control was PBS.

[0036] Experimental steps:

[0037] 1) 4-week-old female NOD mice entered the Experimental Animal Center of Nanjing Medical University and were reared in a clean environment with a temperature of (21±2)°C and a humidity of (35±2)%, 12h:12h day and night without lighting, free to eat and drink, Drinking water was distilled water prepared by the Experimental Animal Center.

[0038] 2) After one week of adaptive feeding, they were randomly divided into 3 groups, 15 in each group, and were injected intraperitoneally wi...

Embodiment 2

[0052] Example 2 Effect of lentinan on the levels of pro-inflammatory and anti-inflammatory cytokines in serum of NOD mice.

[0053] According to the kit instructions, the ELISA method was used to detect the levels of pro-inflammatory and anti-inflammatory cytokines in the mouse serum of Example 1, and the differences between the PBS control group and the lentinan experimental group were compared. The specific steps are:

[0054] 1) Add serum samples and standards of different concentrations (100 μl / well) to the corresponding wells, seal the reaction wells with sealing tape, and incubate at 37°C for 90 minutes (except for blank control wells);

[0055] 2) Shake off the liquid in the wells, add 350 μl of washing solution to each well, let it stand for 30 seconds, shake off the liquid, pat dry on absorbent paper, and repeat this step 4 times;

[0056] 3) Add biotinylated antibody working solution (100 μl / well), seal the reaction well with sealing tape, and incubate at 37°C for ...

Embodiment 3

[0063] Example 3 Effect of Lentinan on CD25 in spleen and pancreatic lymph nodes of NOD mice + Foxp3 + Treg, CD3 + CD8 + Effect of CTLs.

[0064] Analysis of CD25 in mouse spleen and pancreatic lymph nodes in Example 1 by flow cytometry + Foxp3 + Treg and CD3 + CD8 + For the number of CTL cells, compare the differences between PBS and lentinan experimental groups. Specific steps are as follows:

[0065] 1) Put 3 groups of cleaned fresh mouse spleen or pancreatic lymph nodes in a plate filled with RPMI-1640 cell culture medium, grind the spleen or pancreatic lymph nodes with a glass homogenizer, filter and pour into a graduated centrifuge tube, Add culture medium to 6ml;

[0066] 2) 1500rpm / min at room temperature, centrifuge for 5min;

[0067] 3) Discard the supernatant, add Tris-NH to the lower layer of cells 4 Cl (pH7.0), shake for 2 minutes to lyse and destroy red blood cells;

[0068] 4) Add PBS (pH 7.0) containing 0.5% BSA to 6ml, centrifuge at 1500rpm / min at ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a use of lentinan in preparation of a drug for preventing diabetes type 1. The invention discloses a use of lentinan in preparation of a drug for adjuvant treatment on diabetes type 1. Lentinan is injected into the abdominal cavity of an NOD mouse with spontaneous diabetes type 1 and influence produced by lentinan with body immunity adjustment functions on NOD mouse diabetes incidence is observed. Lentinan reduces NOD mouse insulitis incidence through improving CD25, Foxp3 and T cell (Treg) quantity in NOD mouse spleen, pancreas and lymph nodes, inhibiting CD3, CD8 and cytotoxic T cell (CTL) activation and reducing proinflammatory cytokine secretion, improves a serum insulin level, keeps a blood sugar normal level, finally reduces NOD mouse diabetes type 1 incidence and improves an NOD mouse survival rate.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the use of lentinan, in particular to the use of lentinan in the preparation of medicines for preventing type 1 diabetes. Background technique [0002] Diabetes mellitus (DM) has become a common and frequently-occurring disease that seriously affects human health in modern society. In 2010, the International Diabetes Federation (IDF) reported that there were 246 million people with diabetes worldwide, and it is estimated that the number of people with diabetes will increase to 388 million by 2025. In my country, there are nearly 92.4 million diabetic patients, of which type 2 diabetes accounts for 90% to 95%, and the prevalence of type 1 diabetes is also increasing at a rate of 2% to 5%. [0003] Although both type 1 diabetes and type 2 diabetes are the result of the interaction of genetic and environmental factors, there are essential differences between the two. First of all, the pathog...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/715A61P3/10A61K36/06
CPCA61K31/715A61K36/06
Inventor 韩晓张亚琴梅洪梁朱云霞常晓媛
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com